Baracitinib News Tops AAD Annual Meeting Coverage

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Healio was on hand at this year’s American Academy of Dermatology Annual Meeting, covering a range of important dermatology news, including updates on atopic dermatitis, psoriasis and hair disorders.

Here are Healio’s five most-read or most-watched AAD meeting updates and videos from 2022:

VIDEO: Long-term hair growth illustrated with baricitinib in alopecia areata

In this video, Brett A. King, MD, PhD, associate professor of dermatology at the Yale School of Medicine, discusses the 52-week pooled analysis of two double-blind, placebo-controlled phase three trials he presented during the meeting’s news session. Look here.

Long term ruxolitinib cream improves face and body repigmentation

David Rosmarin, MD, Clinical Investigator and Vice President for Research and Education at Tufts Medical Center, presented data from two identical Phase 3 studies, TRuE-V1 and TRuE-V2, which each included more than 300 patients with vitiligo. Read more.

Roflumilast effective in reducing itching in seborrheic dermatitis

This phase 2, parallel-group, double-blind, vehicle-controlled trial enrolled 226 adult patients with seborrheic dermatitis who were randomly assigned to receive roflumilast foam 0.3% (Arcutis) or excipient foam for 8 weeks. Read more.

Trifarotene plus doxycycline effective in the treatment of severe acne

Rapid improvement in severe acne was observed in patients treated with 12 weeks of trifarotene and doxycycline. Read more.

VIDEO: Galderma launches Twyneo cream for acne

In this video, Hilary Baldwin, MD, medical director of the Acne Research Center in Brooklyn, New York, discusses the science behind Twyneo cream. Look here.

Comments are closed.